Survivorship Care
With the aging of the general population and as a result of advances in prevention, screening, and treatment for cancer, the number of adult cancer survivors in the United States is anticipated to reach 20 million by the year 2026. Attention to the healthcare needs of this group is imperative, as they are at risk for immediate, post-treatment, and late effects of cancer therapy. This chapter begins by discussing several topics that are relevant to all cancer survivors, followed by a discussion of several of the major cancer types, a special therapeutic modality (allogeneic hematopoietic cell transplant) and two particularly vulnerable populations (childhood and elderly cancer survivors). Wherever possible, late effects that may be prevented or ameliorated by early detection and treatment are highlighted.
